| Literature DB >> 34948021 |
Jakub W Strawa1, Katarzyna Jakimiuk1, Michał Tomczyk1.
Abstract
The use of plants as traditional medicines is common and has prevailed in many different cultures over time. Polymethoxyflavones (PMFs) are natural polyphenols from the group of flavonoids. Zapotin, a member of the PMFs, is found mainly in citrus plants and is almost exclusively limited to their peels. The chemical structure of zapotin has been questioned from the very beginning, since the structure of flavonoids with a single oxygen atom in the C2' position is extremely rare in the plant kingdom. To clarify this, the structural determination and bio-inspired synthesis of zapotin are discussed in detail in this review. Due to the broad biological potential of PMFs, the complication in the isolation process and characterization of PMFs, as well as their purification, have been estimated by adapting various chromatographic methods. According to available data from the literature, zapotin may be a promising curative agent with extensive biological activities, especially as a chemopreventive factor. Apart from that, zapotin acts as an antidepressant-like, anticancer, antifungal, and antioxidant agent. Finally, accessible studies about zapotin metabolism (absorption, distribution, metabolism, excretion, and toxicity) underline its potential in use as a therapeutic substance.Entities:
Keywords: biological activity; chemistry; flavonoids; polymethoxyflavone; zapotin
Mesh:
Substances:
Year: 2021 PMID: 34948021 PMCID: PMC8705526 DOI: 10.3390/ijms222413227
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Chemical structure of zapotin.
Plants containing zapotin and their traditional uses.
| Species | Family | Location | Parts of Plant | Traditional Uses | References |
|---|---|---|---|---|---|
|
| Rutaceae | not given | bark, seeds, leaves | hypertension, anxiety, insomnia, painkiller | [ |
|
| Rutaceae | Mexico | root | not found | [ |
|
| Rutaceae | Mexico | seeds | antihypertensive | [ |
|
| Rutaceae | Mexico | leaves | gastrointestinal problems | [ |
|
| Fabaceae | Nigeria | root bark | lumbago, pain, gonorrhea, anticonvulsant, antimicrobial, | [ |
|
| Fabaceae | Argentina | fruits | dysentery, expectorant agent, flatulence | [ |
|
| Primulaceae | Poland | herb | heart problems | [ |
|
| Calophyllaceae | India | stem bark | eczema | [ |
|
| Punicaceae | Egypt | peel extract | inflammation, rheumatism, sore throat, snakebite, diabetes, burns | [ |
|
| Primulaceae | Poland | leaves a | respiratory, cardiac, nervous system conditions, expectorant, sedative | [ |
|
| Thymelaeaceae | South Africa | herb | not found | [ |
|
| Myrtaceae | India | fruit | gastrointestinal problems, painkiller | [ |
a—from cultivation and in vitro cultures.
Column chromatography in the separation of zapotin.
| Plant | Part of the Plant | Extract | Separation Conditions | References |
|---|---|---|---|---|
|
| seeds, trunk, and root bark | EtOH |
dissolving in 4% HCl extraction with benzene CC; Al2O3; benzene:Et2O (4:1 crystallization from MeOH or acetone | [ |
| MeOH |
fractionating with EtOAc CC; Silica; CHCl3:MeOH CC; Silica; EtOAc:petroleum ether isolation from the 25% EtOAc in Et2O | [ | ||
|
| seeds | EtOAc |
VLC fractionation with Hex:EtOAc (7:3 | [ |
|
| leaves | EtOH |
extraction with EtOAc CC; Sephadex LH20; el: MeOH RPC18; MeOH, 50–100% RPC18; ACN:MeOH:H2O | [ |
|
| leaves | CHCl3 |
CC; cellulose; MeOH:H2O (7:3 CC; polyamide; MeOH prep. TLC; Silica; prep. TLC; Avicel; acetone:H2O (3:17 CC; Polyamide; MeOH CC; Sephadex LH20; MeOH | [ |
|
| herb | MeOH |
fractionation with Hex and MeOH:H2O, CH2Cl2 and MeOH:H2O RPC8; ACN:H2O RPC18; MeOH:H2O | [ |
High-performance liquid chromatography in the separation of zapotin.
| Plant | Part of the Plant | Extract | Column | Mobile Phase | Conditions | References |
|---|---|---|---|---|---|---|
|
| seeds | MeOH | Restek | 5% AcOH and H2O:MeOH | 30–90% B: 0–50 min, 90% B: 50–55 min | [ |
|
| root bark | MeOH | not given | not given | not given | [ |
|
| herb | Hex/CH2Cl2 | Zorbax RX-C8, | 0.1% THF and H2O:ACN | 25–100% | [ |
Gas chromatography in the separation of zapotin.
| Plant | Part of the Plant | Extract | Column a | Conditions | References |
|---|---|---|---|---|---|
|
| root | not given | not given | 30 to 310 °C; 8 °C/min; | [ |
|
| fruit | MeOH | VF-5MS | 3 min at 70 °C; 10 °C/min to 240 °C, then 5 °C/min to 300 °C, 9 min at 300 °C | [ |
|
| stem bark | petroleum | RESTEK Rtx-5 (0.25 × 30.0 × 0.25) | 3 min at 70 °C; 10 °C/min to 240 °C, then 5 °C/min to 300 °C, 9 min at 300 °C | [ |
|
| peel | not given | Agilent HP-5ms (0.25 × 30.0 × 0.25) | 2 min at 60 °C; | [ |
a—ID [mm], L [m], F [µm]).
Bioactivities of zapotin reported in experimental models in vitro and in vivo.
| Activity | Experimental Model | Exposure/ | Concentration | Efficacy | References |
|---|---|---|---|---|---|
| Anti-viral | RDDP5 assay | not given | 70% ethanolic |
IC50 (µg/mL):
HIV-1 RT RDDP: 0.27 HIV-1 RT RNase H: 2.0 | [ |
| Anti-cancer | K562 | not given | 70% ethanolic |
CC50 (µg/mL):
K562 cells: 0.00031 | [ |
| HL-60 | not given | not given |
induction of differentiation corelated with proliferation arrest ED50 < 8 mg/mL lack of cytotoxicity | [ | |
| LNCaP, DU-145, lung | 24 h incubation with extracts, | MeOH fraction of |
Inhibition of proliferation (IC50):
LNCaP: 2.4 ± 0.2 µg/mL DU-145: 3.3 ± 0.2 µg/mL lung adenocarcinoma: 3.6 ± 0.2 µg/mL healthy VERO cells: 17.9 ± 1.6 µg/mL 3-fold decreased expression of Bcl-2 and a 4-fold increase in Bax levels at 10 µg/mL in LNCaP cells 3.5-fold reduction in FIR and 4.2-fold induction of CCR at 10 µg/mL | [ | |
| A549 cell line | not given | Zapotin, |
inhibition of the growth of neoplast cells through an indirect pathway at the protein level | [ | |
| disk diffusion assay for | not given | 1 μg/disk |
potent cytotoxicity with significant solid tumor selectivity (Colon38, L1210) MCF-7ΔCEM: 250 zone units U251NΔCEM: 400 zone units PANC-1ΔCEM: 400 zone units H-116 ΔCEM: 450 zone units | [ | |
| female | 15 weeks | 1, 5, and 10 μmol/mouse |
Anti-initiation (total tumor number; average tumor number:
1 μmol: 216; 10.8 ± 6.2 5 μmol: 222; 11.1 ± 6.0 10 μmol: 138; 6.9 ± 4.9 Anti-promotion (total tumor number; average tumor number:
1 μmol: 139; 7.0 ± 5.4 5 μmol: 117; 5.9 ± 4.0 10 μmol: 123; 6.2 ± 6.3 Anti-initiation/promotion (total tumor number; average tumor number):
1 μmol: 184; 9.2 ± 4.4 5 μmol: 182; 9.1 ± 6.2 10 μmol: 163; 8.2 ± 5.7 | [ | |
| HeLaPKCεA/E subline |
MTT assay, 72 h Western blot, 1 h 45 PKC activity |
1–25 μM 7.5, 15 and 30 μM 3.75–15 μM |
HeLaWT cells were treated with zapotin for 72 h and the IC50 value was found to be 17.9 ± 1.6 μM cytotoxic effect in cells expressing PKCεA/E activation of recombinant PKCε was dose-dependent PKCδ was down-modulated to a lesser extent by zapotin increasing doses of zapotin (3.75, 7.5, and 15 μM) attenuated the enhanced migration of doxycycline-induced cells overexpressing PKCεA/E at 15 μM, zapotin caused a significant decrease in the level of Bcl-2 by almost 40% compared to the control increasing concentration of zapotin (from 7.5 to 30 mM) caused the formation of autophagosomes and a decline in microtubule-associated protein 1 light chain 3 protein levels | [ | |
| SW480, SW620,HT-29 cell lines, female CF-1 mice |
24 h in the proliferation assay 6, 18, 24, 48 h in flow cytometry | 5.0 or 10.0 mg/kg BW in the induction of ACF, |
antiproliferative properties with HT-29 cells: IC50 at 212 ng/mL for the isolated zapotin compared with 192 ng/mL for the synthetic zapotin zapotin mediated growth inhibition in a dose-dependent manner, with 78% inhibition at 1 µM and an IC50 of 2.74 × 10–7 M (HT-29), 2.29 × 10–7 M (SW480), 5.27 × 10–7 M (SW620) maximum antiproliferative response of zapotin was observed after 5 days treatment with 1 µM (48 h) increased the percentage of apoptotic cells in all three cell lines reduction of ACF by 56% and 67% by zapotin at doses of 5.0 and 10.0 mg/kg zapotin treatment resulted in a reduction in the number of large ACF by 87% and 67% at doses of 5.0 and 10.0 mg/kg BW, respectively | [ | |
| ODC, HepG2 and HL-60 |
18 h in TPA-induced ODC, cell differentiation 48 h in TPA-induced NF-κB assay 24 h in the quantification of apoptosis and cell cycle | 12 μM zapotin in the quantification of apoptosis |
inhibition of the induction of ODC activity by TPA (IC50 = 3.4 ± 1.7 μM) inhibition of TPA-induced NF-κB activity in HepG2 cells stably transfected with NF-κB-luciferase plasmid with an IC50 value of 7.6 ± 3.3 μM significant increase in apoptosis at 3 μM and higher suppression in the G2/M phase of the cycle at 0.75 μM | [ | |
| Anti- | Aroclor 1254-pretreated rats | not given | not given |
DMBA-induced mutagenesis with DMBA-induced preneoplastic lesions with MMOC: 50 µg/mL | [ |
| Vasorelaxant | adhering tissue and arterial rings from 6-month-old rats | 45 min |
| [ | |
| Antimicrobial | suspensions of microorganisms containing 106 CFU/mL | 72 h at 37 °C | water juice peel from |
inhibition zones’ diameter (mm):
| [ |
| Anti- | mice | first dose 60 min before testing, second dose 24, 7, and 1 h before testing | hexane (HCP), ethyl acetate (ECP), and methanol (MCP) extracts from |
induced a reduction in the FST assay HCP at a 30 mg/kg dose; the animals showed a decrease in ambulatory activity and loss of motor coordination MCP did not produce any change in behavior in the experimental animals ECP caused a dose-dependent response in doses in the range of 7.5, 15, and 30 mg/kg; the immobility time was almost the same as that of 60, 90, and 120 mg/kg | [ |